Thomas D. Bird

Thomas D. Bird

Auto-generated profile, based on publicly available information

Thomas D. Bird

Division of Medical Genetics, University of Washington School of Medicine, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
CBCraig Bennett
Craig Bennett
VLV. H. Lawson
V. H. Lawson
KBK. L. Brickell
K. L. Brickell
KIK. Isaacs
K. Isaacs
WSW. Seltzer
W. Seltzer
TBT. D. Bird
T. D. Bird
Background: Hereditary motor-sensory neuropathy or the Charcot-Marie-Tooth syndrome is known to represent considerable genetic heterogeneity. Onset is usually in childhood, adolescence, or young adulthood. The objective of this study was to define late-onset forms of the disorder. Methods: A clinical and genetic study of families with uniformly late onset of peripheral neuropathy was performed in a university neurogenetics setting. Results: Six families were identified with consistently late onset of a primarily axonal neuropathy. Median age at symptom onset was 57 years (range 35–85 years) of a mixed motor and sensory neuropathy with electrophysiologic characteristics of an axonal rather than demyelinating condition. There was a possible association with deafness. Two families showed autosomal dominant inheritance whereas four families had only one affected generation with an excess of males. An extensive mutation screen of nine genes known to cause Charcot-Marie-Tooth was negative. Conclusions: There are late-onset forms of hereditary axonal neuropathies. The genetic causes remain unknown and genetic heterogeneity within this entity is likely.

24 February 2018 in Journal of Huntington's Disease
Verified
Journal Article
Closed access
PDF file
DTDebby W. Tsuang
Debby W. Tsuang
TGTiffany A. Greenwood
Tiffany A. Greenwood
SJSuman Jayadev
Suman Jayadev
MDMarie Y. Davis
Marie Y. Davis
ASAndrew Shutes-David
Andrew Shutes-David
TBThomas D. Bird
Thomas D. Bird
Background: Psychotic symptoms of delusions and hallucinations occur in about 5% of persons with Huntington’s disease (HD). The mechanisms underlying these occurrences are unknown, but the same symptoms also occur in schizophrenia, and thus genetic r

2 December 2022 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
AVAnastasia Vishnevetsky
Anastasia Vishnevetsky
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
ESElison Sarapura‐Castro
Elison Sarapura‐Castro
MIMiguel Inca‐Martinez
Miguel Inca‐Martinez
DRDanielle Rabinowitz
Danielle Rabinowitz
TBThomas Bird
Thomas Bird

1 April 2025 in Neurology Clinical Practice
Verified
Journal Article
Open access
CCCiaran Considine
Ciaran Considine
CEClare M. Eddy
Clare M. Eddy
SFSamuel Frank
Samuel Frank
SKSandra K. Kostyk
Sandra K. Kostyk
MOMayke Oosterloo
Mayke Oosterloo
DCDaniel O Claassen
Daniel O Claassen
Huntington disease (HD) is a genetic neurodegenerative disorder. Given the focus on motor manifestations, nonmotor symptoms are frequently underappreciated in clinical evaluations, despite frequently contributing to primary functional impairment. A diagnosis of motor-onset as the definition of manifest symptoms misrepresents the complex nature of HD presentation. Despite recent attempt to integrate nonmotor diagnostic criteria, practical guidelines are necessary to inform clinical diagnosis. We propose an HD diagnostic framework and staging system that prioritizes genetic testing, integrates motor and nonmotor symptom considerations in the determination of clinical disease onset and severity, and acknowledges the secondary role of clinically indicated diagnostic assessments, incorporating the broad symptom profiles observed in clinical practice. The proposed diagnostic criteria more accurately reflect the presentation of HD and provide greater opportunities for health care professionals to provide appropriate clinical care guidelines for adults with gene-expanded HD.

18 September 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
CYChang-En Yu
Chang-En Yu
SCSunny Chen
Sunny Chen
SJSuman Jayadev
Suman Jayadev
TBThomas Bird
Thomas Bird
Age of onset modifiers are of considerable importance in Alzheimer and related dementias. Arboleta-Valesquez et al, reporting on a single PSEN1 subject, suggested that homozygosity for the Christchurch variant of APOE could represent such a modifier. We studied APOE Christchurch and Kloth-VS genotypes of five dementia age of onset outliers who carried their families’ pathogenic variant, but were asymptomatic at ages beyond the families’ average age of onset. Four age of onset outliers with PSEN1/2 and MAPT mutations did not carry the Christchurch variant and a fifth individual was also determined to not be homozygous for this variant. Among them, only one subject (APOE ε3/ε3) carries the Klotho-VS heterozygous genotype. From a small but informative sample of five age of onset outliers we show that neither the APOE Christchurch nor the Klotho-VS variant is a common age of onset modifier for three genetic forms of dementia. Larger studies of this association and further research is required to identify additional genetic modifiers.

16 June 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
IJIan P Johnson
Ian P Johnson
TPTia M Peterson
Tia M Peterson
KGKathryn Gudsnuk
Kathryn Gudsnuk
CKC Dirk Keene
C Dirk Keene
TBThomas D Bird
Thomas D Bird
MCMeredith M Course
Meredith M Course
Circular RNAs (circRNAs) are emerging as a promising object of study in Alzheimer's disease (AD) pathogenesis. Expression differences in circRNAs have been correlated with disease; however, the presence of pathogenic variants has not been observed until now. Here, we examine circRNAs derived from two AD-related genes, presenilin 1 ( PSEN1 ) and presenilin 2 ( PSEN2 ), in the prefrontal cortex from individuals with familial AD, identifying four variants in circRNAs derived from PSEN1 (I143T, S212Y, M146L) and PSEN2 (N141I). The discovery of pathogenic variants in PSEN1 and PSEN2 circRNAs marks a first step in determining whether they play a role in AD etiology.